Mochida Pharmaceutical (4534) Stock Overview
Manufactures and sells pharmaceuticals and healthcare products in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
4534 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mochida Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,085.00 |
| 52 Week High | JP¥3,625.00 |
| 52 Week Low | JP¥2,836.00 |
| Beta | -0.021 |
| 1 Month Change | -0.80% |
| 3 Month Change | -4.34% |
| 1 Year Change | -7.63% |
| 3 Year Change | -2.68% |
| 5 Year Change | -24.11% |
| Change since IPO | -20.67% |
Recent News & Updates
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Sep 24
Mochida Pharmaceutical (TSE:4534) Has Announced A Dividend Of ¥40.00
Sep 02Recent updates
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Sep 24Mochida Pharmaceutical (TSE:4534) Has Announced A Dividend Of ¥40.00
Sep 02Mochida Pharmaceutical (TSE:4534) Has Affirmed Its Dividend Of ¥40.00
Jul 24Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Jul 10Mochida Pharmaceutical (TSE:4534) Has Announced A Dividend Of ¥40.00
Mar 04Mochida Pharmaceutical (TSE:4534) Is Due To Pay A Dividend Of ¥40.00
Dec 04Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Sep 06Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Aug 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Aug 08Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Jul 25Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Jul 11Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Mar 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Mar 02Shareholder Returns
| 4534 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 4.6% | 0.05% | 0.2% |
| 1Y | -7.6% | -7.0% | 19.8% |
Return vs Industry: 4534 matched the JP Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: 4534 underperformed the JP Market which returned 19.8% over the past year.
Price Volatility
| 4534 volatility | |
|---|---|
| 4534 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 4534 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4534's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1913 | 1,508 | Naoyuki Mochida | www.mochida.co.jp |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia.
Mochida Pharmaceutical Co., Ltd. Fundamentals Summary
| 4534 fundamental statistics | |
|---|---|
| Market cap | JP¥109.19b |
| Earnings (TTM) | JP¥6.72b |
| Revenue (TTM) | JP¥109.05b |
Is 4534 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4534 income statement (TTM) | |
|---|---|
| Revenue | JP¥109.05b |
| Cost of Revenue | JP¥53.69b |
| Gross Profit | JP¥55.36b |
| Other Expenses | JP¥48.64b |
| Earnings | JP¥6.72b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 189.45 |
| Gross Margin | 50.76% |
| Net Profit Margin | 6.16% |
| Debt/Equity Ratio | 0% |
How did 4534 perform over the long term?
See historical performance and comparisonDividends
Does 4534 pay a reliable dividends?
See 4534 dividend history and benchmarks| Mochida Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 01 2025 |
| Days until Ex dividend | 39 days |
| Days until Dividend pay date | 24 days |
Does 4534 pay a reliable dividends?
See 4534 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 10:58 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mochida Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taku Ouchi | SMBC NIKKO |